June 12, 2020 / 1:58 PM / 25 days ago

BRIEF-Karolinska Development: Aprea Therapeutics Presents Positive Results From Phase 1B/2 Study

June 12 (Reuters) - Karolinska Development AB:

* KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY APREA THERAPEUTICS PRESENTS POSITIVE RESULTS FROM A PHASE 1B/2 STUDY OF APR-246 AND AZACITIDINE IN MDS AND AML

* OVERALL RESPONSE RATE (ORR) OF 28 EVALUABLE MDS PATIENTS REACHED 75%, WITH A 57% COMPLETE REMISSION (CR) RATE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below